Download presentation
Presentation is loading. Please wait.
1
Clinical Trials with Two Endpoints
2
EXAMPLES HIV Vaccine Trial: Outcome 1: Incidence of HIV infection Outcome 2: Reaching Viral Set-point Cardiovascular: Stroke Heart Attack Cognitive: Evaluation of Memory Occurrence of Dementia Insomnia: Time Till Sleep Length of Continuous Sleep Diet: Pounds lost MmHg BP Lowered
3
Difficulty: Want an overall test that rejects the null only 5% of the time. Somehow, combine two endpoints. There are better ways than Bonferroni that can consider when Modest effects are seen in each outcome. Dealing with the difficulty: Combine Endpoints into a Composite Endpoint. Here, you condense results into a single outcome. May complication interpretation of statistic (Burden of Illness Scores, total time awake at night, lost 10 lbs or lowered BP ) Combine Tests. Perform a statistical test on each endpoint separately, and then consider results from both tests together. Combine P-values.
4
Two Outcomes: H 0 : Θ 1 =0, Θ 2 =0 H A : Θ 1 ≥0, Θ 2 ≥0 (with one strict inequality) How do you test this hypothesis? ONE-SIDED TESTS Why? Believe treatment can only be beneficial Only care if treatment can be beneficial One Outcome: H o : Θ=0 H A : Θ > 0 Reject when Z 1 > α 0.05
5
EXAMPLE of a STUDY with TWO OUTCOMES: DIET: Outcome 1: Weight Loss Outcome 2: Blood Pressure Lower W i = Starting Weight – Final Weight BP i =Starting SBP – Final SBP
6
Option 1: Simes Test Reject H 0 when max(Z 1,Z 2 ) > k x or min(Z 1,Z 2 ) > k n
7
Option 2: Fisher’s Test Reject H 0 when (Z 1 Z 2 ) > k
8
Option 3: Linear Combination of Z Statistics Reject H 0 when Z 1 + Z 2 > k
9
Options 4 - 6: Weighted Versions of Statistics Reject H 0 when w 1 Z 1 + w 2 Z 2 > k When w 1 is large, rejection is primarily based on Z 1
10
Ideal Test? Most Powerful? Only one alternative ( θ 1, θ 2 ) Reject H o when Z 1 θ 1 +Z 2 θ 2 >k H A : E(Z 1 ) = θ 1 E(Z 2 ) = θ 2
11
Ideal Test? Most Powerful? Only one alternative ( θ 1, θ 2 ) Reject H o when Z 1 θ 1 +Z 2 θ 2 >k H A : E(Z 1 ) = θ 1 E(Z 2 ) = θ 2
12
Ideal Test? Most Powerful? ( θ 1, θ 2 ) Reject H o when Z 1 θ 1 +Z 2 θ 2 >k (Z 1,Z 2 ) Z 1 θ 1 +Z 2 θ 2
13
Best test statistic under known alternative: Z 1 θ 1 + Z 2 θ 2 Unknown (θ 1,θ 2 )? Estimate the parameters from the data: When there are no restrictions on the Parameter space However, by believing our treatment can only be beneficial, we implicitly State θ 1, θ 2 ≥ 0 Z 2 > 0 otherwise Z 1 > 0 otherwise
14
Rejection Region for
15
Likelihood Ratio Test Switch notation, return to variation of original example 1) Assume subjects are paired. 2) Let X i1,X i2 be the difference in weight and blood pressure change for Pair i. TREATMENT WORK ≈ μ 1 ≡ E(X 1 ) > 0 and/or μ 2 ≡ E(X 2 ) > 0 Density: Just need to find the μ that maximizes the denominator. And then can Use 2*log(λ) as the likelihood ratio test. LR
16
Likelihood Ratio Test (Continued) x 1 > 0 otherwise x 2 > 0 otherwise MLE’s (assuming X 1 and X 2 are independent) log …(skipping the algebra) Always use LRT? --It is very difficult to maximize μ when X i1 and X i2 are not independent Use LRT for POC HIV Vaccine Trial? --The Z statistics for incidence of viral infection and reaching viral set-point are independent.
17
Properties of Likelihood Ratio Test Combining Most Powerful Rejection Regions:
18
Properties of Likelihood Ratio Test Combining Most Powerful Rejection Regions:
19
Properties of Likelihood Ratio Test Combining Most Powerful Rejection Regions:
20
R α (Θ) = The rejection region that gives the most powerful α-level test under the alternative hypothesis, Θ = (θ 1,θ 2 ). p α (Θ) = The power of the most powerful α-level test under the alternative hypothesis, Θ = (θ 1,θ 2 ),. Uniformly Most Powerful Invariant Test (UMPI) Notation: If we can write the rejection region as the union of R α (Θ) such that p α (Θ) is the same for equivalent Θ’s, we will say that test has composition invariance. When does composition invariance imply that the test is Uniformly Most Powerful Invariant? THE END Question
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.